Clinical Trial Update: SIRIUS - Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SIRIUS) will evaluate an initial triple therapy—an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, and sotatercept—fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• Endothelin receptor antagonist
• Phosphodiesterase-5 inhibitor
• Sotatercept (sotatercept)

Snippet

Sponsor: Philipps University Marburg | Conditions: Pulmonary Arterial Hypertension (PAH) | Phase 2 | Status: NOT_YET_RECRUITING